ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "HLA antibodies"

  • 2022 American Transplant Congress

    Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients

    K. Progar1, K. Kurwicki2, N. Nesselhauf3, J. Hagopian4, S. January5, H. Wijeweera6, M. McCloskey7, M. Merzkani8, R. Delos Santos9

    1Transplant, Barnes-Jewish Hospital, St. Louis, MO, 2SSM Health Saint Louis University Hospital, Saint Louis, MO, 3Barnes-Jewish Hospital, Edwardsville, IL, 4Pharmacy, University of Michigan, Ann Arbor, MI, 5Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, 6Washington University, Saint Louis, MO, 7Barnes-Jewish Hospital, St. Louis, MO, 8Washington University, St Louis, MO, 9Transplant, Washington University, St. Louis, MO

    *Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
  • 2022 American Transplant Congress

    HLA DSA May Not Be Detected in Many Solid Organ Recipients

    J. C. Quon1, R. M. Lestz2, J. Menteer2, N. Fotiadis2, L. A. Baxter-Lowe2

    1Keck School of Medicine, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA

    *Purpose: Clinically significant HLA antibodies may not be detected if their unique HLA epitopes are not represented in the single antigen reagents that are routinely…
  • 2022 American Transplant Congress

    Local Intragraft Humoral Immune Response in Chronic Lung Allograft Dysfunction

    E. Miyamoto1, S. C. Juvet2, D. Vosoughi2, J. Wang2, J. Al-Refaee2, T. Daigneault2, A. Duong2, S. Moshkelgosha2, S. Keshavjee2, K. Tinckam2, A. Chruscinski3, D. Hwang4, T. Martinu2

    1Tenri Hospital Japan, University Health Network Canada, Nara, Japan, 2University Health Network, Toronto, ON, Canada, 3Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, 4Sunnybrook Health Science Centre, Toronto, ON, Canada

    *Purpose: Donor HLA-specific antibody (DSA) and antibody against self-antigens (self-antigen antibody) can cause injury and lead to chronic lung allograft dysfunction (CLAD) after lung transplantation…
  • 2022 American Transplant Congress

    Which is More Important for Predicting De Novo DSA Production, B Cell Epitope (EPLET) or T Cell Epitope (PIRCHE) Analysis ?

    T. Kobayashi1, T. Tomosugi2, S. Sakamoto2, S. Ashimine1, K. Iwasaki1, M. Niemann3, E. Spierings4, Y. Miwa1, M. Okumura1, K. Ishiyama1, A. Takeda2, N. Goto2, S. Narumi2, Y. Watarai2

    1Aichi Medical University School of Medicine, Nagakute, Japan, 2Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3PIRCHE AG, Berlin, Germany, 4UMC Utrecht, Utrecht, Netherlands

    *Purpose: De novo donor-specific antibodies (dnDSA) can cause chronic ABMR, resulting in poor prognosis. Recently, mismatch at B cell epitope level, i.e. EPLET mismatch, has…
  • 2022 American Transplant Congress

    Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation

    J. D. Motter1, K. Jackson1, A. Massie1, J. Garonzik-Wang2, D. Segev1

    1Johns Hopkins University, Baltimore, MD, 2University of Wisconsin-Madison, Madison, WI

    *Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
  • 2022 American Transplant Congress

    Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study

    P. F. Halloran1, L. G. Hidalgo2, Z. Demko3, A. Prewett3, J. Reeve1, C. Lawrence4, D. Lowe4, P. Billings3, .. and the Trifecta Investigators5

    1Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, 2University of Wisconsin, Madison, WI, 3Natera Inc., San Carlos, CA, 4One Lambda Inc., West Hills, CA, 5., ., AB, Canada

    *Purpose: Trifecta (ClinicalTrials.gov #NCT04239703) is a prospective, IRB-approved, consented study of the relationships among three central tests in kidney transplant indication biopsies: molecular biopsy diagnoses…
  • 2022 American Transplant Congress

    Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up

    A. Vo1, J. Tang1, N. Ammerman1, E. Huang1, X. Zhang2, M. Haas3, A. Peng1, R. Najjar1, S. Williamson1, C. Meyers1, S. Sethi1, K. Lim1, M. Gillespie1, N. Badash1, S. Jordan1

    1Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, 2HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, 3Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…
  • 2022 American Transplant Congress

    Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)

    J. Lee, T. Sam, J. Van Zyl, S. Mckean, L. Fuller, N. Wilson, A. Dao, R. Gottlieb, S. Hall, R. Patel

    Baylor University Medical Center, Dallas, TX

    *Purpose: AMR in HTR portends poor clinical outcomes. Reported mortality range between 20-50%, with higher rates reported for late AMR occurring at least 1 year…
  • 2022 American Transplant Congress

    Dynamic Changes of Serum Soluble B Cell Activating Factor in Kidney Transplant with De Novo Donor Specific Antibody

    S. Wu1, X. Su1, Y. Gao1, Y. Wei1, Q. Ye1, M. Huang2, Y. Chen1, J. Wang1, Q. Zhang3, Q. Fu1, J. Li2, H. Huang2, B. Xu2, H. Zhang1, L. Liu2, C. Wang2

    1Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 3Charité - Universitätsmedizin Berlin, Berlin, Germany

    *Purpose: De novo donor specific antibody (dnDSA) plays a crucial role in the development of antibody mediated rejection (ABMR) and is correlated to the worse…
  • 2022 American Transplant Congress

    Simultaneous Liver/ Kidney Transplant Reduces Both Donor Specific and Non-Donor Specific HLA Antibodies

    X. Zhang, S. Wisel, I. Kim, S. Jordan

    Cedars Sinai Medical Center, Los Angeles, CA

    *Purpose: Kidney allografts can be transplanted across strong donor specific antibody (DSA) barriers in simultaneous liver/kidney transplant (SLK) recipients. It is suggested that preformed DSAs…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 47
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences